Oncotarget,
The final cover paper for Oncotarget's 2022 Volume 13 has been selected: "Real-world survival analysis by tumor mutational…
The final cover paper for Oncotarget's 2022 Volume 13 has been selected: "Real-world survival analysis by tumor mutational…
#PaperoftheDay: "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study…
#PaperoftheDay: "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study…
Researchers conducted a multi-site cohort study of tumor mutational burden among 667 patients diagnosed with stage IV non-small…
#FactFriday: #Neoantigens are new #proteins that form on #cancer cells when certain #mutations occur in tumor #DNA. #Immunotherap…
Researchers conducted a multi-site cohort study of tumor mutational burden among 667 patients diagnosed with stage IV non-small…
#TrendingWithImpact: Researchers analyzed tumor mutational burden (TMB) in non-small cell #lungcancer among hundreds of…
This week's Oncotarget paper #TrendingWithImpact was published on January 31, 2022, and entitled, "Real-world survival analysis…
Researchers conducted a multi-site cohort study of tumor mutational burden among 667 patients diagnosed with stage IV non-small…
Researchers conducted a multi-site cohort study of tumor mutational burden among 667 patients diagnosed with stage IV non-small…
#TrendingWithImpact: Researchers from The University of Utah, University of Minnesota, Moffitt Cancer Center, Baptist Health…
#TrendingWithImpact: Researchers conducted a multi-site cohort study of tumor mutational burden among 667 patients diagnosed…
NEW #PaperoftheDay: "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S.